NATCO Pharma Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Operating Revenue	45,602	44,295	39,988	27,071	19,448	20,521
Other Revenue	24	24	32	14	14	40
Revenue	45,626	44,319	40,020	27,085	19,462	20,561
Revenue Growth (YoY)	6.60%	10.74%	47.76%	39.17%	-5.34%	7.37%
Cost of Revenue	8,226	7,274	7,487	6,544	5,845	5,318
Gross Profit	37,400	37,045	32,533	20,541	13,617	15,243
Selling, General & Admin	6,927	5,991	5,309	4,625	4,806	4,390
Other Operating Expenses	11,838	9,029	9,599	6,072	5,952	4,634
Operating Expenses	21,321	17,383	16,827	12,443	12,383	10,310
Operating Income	16,079	19,662	15,706	8,098	1,234	4,933
Interest Expense	-291	-170	-120	-148	-132	-93
Interest & Investment Income	1,905	1,905	1,013	513	392	566
Currency Exchange Gain (Loss)	198	198	103	214	103	40
Other Non Operating Income (Expenses)	-413	271	14	130	-3	30
EBT Excluding Unusual Items	17,587	21,866	16,716	8,807	1,594	5,476
Merger & Restructuring Charges	-	-	-	-291	-11	-
Gain (Loss) on Sale of Investments	14	14	-7	-52	12	-
Gain (Loss) on Sale of Assets	901	901	-17	178	427	320
Asset Writedown	-30	-30	-	-23	-	-
Pretax Income	18,635	22,914	16,735	8,619	2,022	5,796
Income Tax Expense	3,080	4,080	2,852	1,466	322	1,372
Earnings From Continuing Operations	15,555	18,834	13,883	7,153	1,700	4,424
Net Income to Company	15,555	18,834	13,883	7,153	1,700	4,424
Minority Interest in Earnings	17	20	-	-	-	-15
Net Income	15,572	18,854	13,883	7,153	1,700	4,409
Net Income to Common	15,572	18,854	13,883	7,153	1,700	4,409
Net Income Growth	-16.51%	35.81%	94.09%	320.76%	-61.44%	-4.32%
Shares Outstanding (Basic)	179	179	179	183	182	182
Shares Outstanding (Diluted)	179	179	179	183	182	182
Shares Change (YoY)	-0.00%	-0.21%	-1.67%	0.08%	-0.04%	0.02%
EPS (Basic)	86.94	105.26	77.34	39.18	9.32	24.20
EPS (Diluted)	86.94	105.26	77.34	39.18	9.32	24.16
EPS Growth	-16.51%	36.10%	97.40%	320.39%	-61.42%	-4.35%
Free Cash Flow	-	12,957	8,722	7,028	-1,863	442
Free Cash Flow Per Share	-	72.34	48.59	38.50	-10.21	2.42
Dividend Per Share	5.000	6.000	9.500	5.500	4.500	5.250
Dividend Growth	-16.67%	-36.84%	72.73%	22.22%	-14.29%	-22.22%
Gross Margin	81.97%	83.59%	81.29%	75.84%	69.97%	74.13%
Operating Margin	35.24%	44.37%	39.25%	29.90%	6.34%	23.99%
Profit Margin	34.13%	42.54%	34.69%	26.41%	8.73%	21.44%
Free Cash Flow Margin	-	29.24%	21.79%	25.95%	-9.57%	2.15%
EBITDA	17,844	21,442	17,506	9,669	2,600	6,066
EBITDA Margin	39.11%	48.38%	43.74%	35.70%	13.36%	29.50%
D&A For EBITDA	1,765	1,780	1,800	1,571	1,366	1,133
EBIT	16,079	19,662	15,706	8,098	1,234	4,933
EBIT Margin	35.24%	44.37%	39.25%	29.90%	6.34%	23.99%
Effective Tax Rate	16.53%	17.81%	17.04%	17.01%	15.93%	23.67%
Revenue as Reported	48,463	47,840	41,269	28,117	20,438	21,557
Advertising Expenses	-	-	-	-	326	211

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.